UmbREALungNCT06726720
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Nov 18, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 12 versions: 9 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 7 words
- Trial sites expanded: 52 → 85 locations
- Trial sites reduced: 70 → 52 locations
- Secondary endpoints: details revised at 10 of 14 entries
- Minor Trial sites expanded: 52 → 70 locationsv11
- Minor Study sites: 40 to 52v9
- Minor Study sites: 39 to 40v7
- Minor Study sites: 28 to 39v6
Show 3 earlier versionsHide 3 earlier versions
- Minor Study sites: 21 to 28v4
- Minor Study sites: 2 to 21v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
- Primary endpoints: 3 to 4
- Study sites: 0 to 2
- Start date changed from estimate of Dec 11, 2024 to Dec 16, 2024
- Secondary endpoints: 1 to 14
- Study title expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (14)
Show 9 moreShow less
Arms and interventions
Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in resectable NSCLC
Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in Unresectable NSCLC
Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in Metastatic NSCLC
Sites
85 sites in 2 countries
France 55, Germany 30